Patent ID: 9486441
Filing Date: 2016-11-08
CPC Classification: A61K,A61P

Claim Text:
1. A method for reducing the severity of symptoms in a subject suffering from a neurodegenerative disease or disorder, the method comprising administering to the subject a therapeutic amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises at least 8.0 mg of a composition consisting essentially of an at least 80% or above pure or synthetic compound selected from the group consisting of: or a mixture of compounds I-62 and I-63, wherein the pharmaceutical composition is further characterized by: the therapeutic amount being effective to modulate phosphatase activity of protein phosphatase 2A (PP2A) in nerve cells, containing less than 10% of caffeine, caffeic acid, and chlorogenic acid; and the neurodegenerative disease is characterized by: (1) abnormal methylation of protein phosphatase 2A (PP2A) and hyperphosphorylation of tau; or (2) abnormal methylation of protein phosphatase 2A (PP2A) and abnormal phosphorylation of alpha-synuclein; or (3) abnormal protein phosphatase 2A (PP2A) activity; hyperphosphorylation of tau, and abnormal phosphorylation of alpha-synuclein; or a combination thereof; wherein I-62 and I-63 are the only compounds in the composition that modulate PP2A activity in nerve cells.